Once-daily intravenous busulfan as myeloablative, reduced-toxicity conditioning regimen: results in young and adult patients with hematological malignant and nonmalignant diseases. Hematology Meeting Reports (formerly Haematologica Reports), [S. l.], v. 2, n. 6, 2009. DOI: 10.4081/hmr.v2i6.771. Disponível em: https://journals.pagepress.org/hmr/article/view/771. Acesso em: 20 jun. 2025.